chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 36.0
Sex: F
Vaccine: TDAP
Symptoms: Product storage error
Clinical narrative: medication error due to administering dose post temperature excursion outside acceptable guidelines for excursion stability standard, with no reported adverse event; Initial information received on 19-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 36 years old female patient who experienced medication error due to administering dose post temperature excursion outside acceptable guidelines for excursion stability standard, with no reported adverse event while receiving vaccine Diphtheria-2/tetanus/5 ac pertussis vaccine [adacel].   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included HPV VACCINE (HPV VACCINE) for Immunisation.  On 25-Mar-2022, the patient received a  dose of 0.5 ml of suspect Diphtheria-2/tetanus/5 ac pertussis vaccine Suspension for injection (strength :unknown) lot C5963AA, expiry date :03-jun-2023 via intramuscular route in unknown administration site for immunization.  On 25-MAR-2022 the patient developed a non-serious medication error due to administering dose post temperature excursion outside acceptable guidelines for excursion stability standard, with no reported adverse event (product administration error) (latency :same day) following the administration of Diphtheria-2/tetanus/5 ac pertussis vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (medication error due to administering dose post temperature excursion outside acceptable guidelines for excursion stability standard, with no reported adverse event).  At time of reporting, the outcome was Unknown for the event medication error due to administering dose post temperature excursion outside acceptable guidelines for excursion stability standard, with no reported adverse event.     This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  01068650: 01068813: 01068814: 01068816: 01068817: 01068825: 01068827: 01068828: 01068830: 01068832: 01068834: 01068835: 01068838:
Sex: F
Vaccine: TDAP
Symptoms: Medication error, No adverse event, Product storage error, Wrong technique in product usage process
Clinical narrative: medication error due to administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event; Adacel reached negative 2.1c from 07mar2022 until 31mar2022 due to temperature excursion due to a refrigerator malfunction with no reported adverse event; Initial information received on 19-Apr-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case is linked to cases 2022SA143416(CLUSTER) and 2022SA143406(CLUSTER).  This case involves a 54 years old female patient who experienced adacel reached negative 2.1c from 07mar2022 until 31mar2022 due to temperature excursion due to a refrigerator malfunction with no reported adverse event and medication error due to administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event while receiving vaccine diphtheria-2/tetanus/5 ac pertussis vaccine [Adacel].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included varicella zoster vaccine rge (cho) (Shingrix) for Prophylactic vaccination.  On 25-Mar-2022, the patient received a  dose of suspect diphtheria-2/tetanus/5 ac pertussis vaccine lot C5963AA via intramuscular route in the right deltoid for immunization.  Adacel reached negative 2.1c from 07mar2022 until 31mar2022 due to temperature excursion due to a refrigerator malfunction with no reported adverse event (product temperature excursion issue). On 25-MAR-2022, same day, the patient developed medication error due to administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event (Wrong technique in product usage process).  Action taken: Not applicable for both  Corrective treatment: Not reported for both  Outcome: Unknown for both   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  01068650: 01068813: 01068814: 01068816: 01068817: 01068825: 01068827: 01068828: 01068830: 01068831: 01068834: 01068835: 01068838:
Age: 43.0
Sex: F
Vaccine: TDAP
Symptoms: No adverse event, Product storage error
Clinical narrative: administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event; Initial information received on 19-Apr-2022 regarding an unsolicited valid non-serious case received via other health professional.  This case concerns a 43 years old female patient who experienced administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event while receiving vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (Adacel).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included: Flu   On 18-Mar-2022, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE at a dose of 0.5 ml with lot C5873AA via intramuscular route in the right deltoid for Immunization.  On 18-Mar-2022 the patient developed administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event (product storage error) (same day)  following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE. Reportedly negative 2.1 C from 07-Mar2022 until 31-Mar-2022 Did it occur due to a human error: No. Does extended stability data cover the excursion: No and in case of negative advice: was the product used by/ administered to the patient: Yes-14   Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event).  At time of reporting, the outcome was Unknown for the event administering dose post temperature excursion outside acceptable guidelines per stability standard with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: RAB
Symptoms: Inappropriate schedule of product administration
Clinical narrative: but did state the clinic has a protocol for deviation of dose by one day, and the patient did come on 18Apr2022 to receive her missed dose with no reported adverse event; Initial information received on 19-Apr-2022 regarding an unsolicited valid non-serious case received from a other health professional via call canter.  This case involves a patient of unknown gender and age reported that the clinic has a protocol for deviation of dose by one day, and the patient did come on 18-Apr-2022 to receive her missed dose with no reported adverse event while receiving vaccine Rabies (Hdc) Vaccine [Imovax Rabies].  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On 18-Apr-2022, the patient received a dose of suspect rabies (HDC) vaccine lot T1E943M and expiry date: 14-Oct-2022 (dose, route, strength, formulation, frequency: unknown) in unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a non-serious event "but did state the clinic has a protocol for deviation of dose by one day, and the patient did come on 18apr2022 to receive her missed dose with no reported adverse event" (inappropriate schedule of product administration) (latency unknown) following the administration of rabies (HDC) vaccine.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (inappropriate schedule of product administration).  At time of reporting, the outcome was Unknown for the event inappropriate schedule of product administration.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 21.0
Sex: M
Vaccine: MNQ
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: received a MENACTRA vaccine at her pharmacy that had expired with no reported adverse event; Initial information received on 20-Apr-2022 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 21 years old male patient who received a menactra vaccine at her pharmacy that had expired with no reported adverse event while receiving vaccine Meningococcal A-C-Y-W135 (D CONJ) vaccine [Menactra].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 18-Apr-2022, the patient received once a first dose, o.5ml of suspect Meningococcal A-C-Y-W135 (D CONJ) vaccine [Menactra] (strength: standerd, form: unknown) via intramuscular route (lot: U6921AA, expiry date: 17-Apr-2022) in the left arm for immunization.  On 18-APR-2022 the patient reported that, received a menactra vaccine at her pharmacy that had expired with no reported adverse event (expired product administered) (Latency: same day) following the administration of Meningococcal A-C-Y-W135 (D CONJ) vaccine [Menactra].  It was reported that, Pharmacist stated that a patient received a MENACTRA vaccine on 18APR2022 at her pharmacy that had expired on 17APR2022. Pharmacist asked if there was a 1 day grace period for expired products. Pharmacist asked how to proceed. This situation was reported as a medication error due to administration of expired Menactra.  Action taken: not applicable.  Outcome: Unknown    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 16.0
Sex: F
Vaccine: MNQ
Symptoms: Injection site rash
Clinical narrative: The patient now has a rash noted at both injection sites; Initial information received on 20-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 16 years old female patient who had a rash noted at both injection sites after receiving vaccine meningococcal a-c-y-w135 (d conj) vaccine [Menactra].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Meningococcal vaccine b (meningococcal vaccine b) for Prophylactic vaccination.  On 11-Apr-2022, the patient received a 0.5 ml dose of suspect meningococcal a-c-y-w135 (d conj) vaccine Solution for injection, expiry date: 15-Apr-2022, lot U6920AB via intramuscular route in the left arm for Immunization.  On an unknown date the patient developed a non-serious event the patient now has a rash noted at both injection sites (vaccination site rash) (unknown latency) following the administration of meningococcal a-c-y-w135 (d conj) vaccine.  It was reported that "advised that she would have to follow up with the Meningitis B manufacturer for reaction symptoms"  Action taken: Not applicable.  It was not reported if the patient received a corrective treatment for the event.  Outcome: Unknown
Age: 0.75
Sex: F
Vaccine: HIBV
Symptoms: Extra dose administered, Medication error, No adverse event
Clinical narrative: patient was administered two doses of ACTHIB on 21APR2022 with no reported adverse event; Initial information received on 21-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 9 months old female patient who was administered two doses of hib (prp/t) vaccine (Act-Hib) on 21apr2022 with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included pneumococcal vaccine conj 7v (crm197) (Prevnar); diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (Dtap); and Rotavirus Vaccine.   On 21-Apr-2022, the patient received 0.5ml doses totaling 1.0 ml of suspect hib (prp/t) vaccine lot U7178AA and expiry date: 30-Nov-2022 (strength, frequency was unknown) via intramuscular route in the left thigh and right thigh for Immunization.Lyophilized powder vial (Lot:UJ614AB Expiration date: 12-Mar-2023) Diluent (Lot: U7178AA Expiration date: 30-NOV-2022)   On 21-Apr-2022, (Latency: same day) the patient was administered two doses of acthib with no reported adverse event (extra dose administered)  Action taken : not applicable.  Outcome: Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: YF
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: Administered Yellow Fever Vaccine via intramuscular instead of subcutaneous does it need to be repeated with no adverse event; Initial information received on 22-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves an unknown age and unknown gender patient who was administered yellow fever vaccine - US [YF-VAX] via intramuscular instead of subcutaneous does it need to be repeated with no adverse event.     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received unknown dose, total, once of suspect yellow fever vaccine form: injection lot number not reported via intramuscular route in unknown administration site for immunization.   On an unknown date the patient was administered yellow fever vaccine via intramuscular instead of subcutaneous does it need to be repeated with no adverse event (incorrect route of product administration) (unknown latency).  Caller stated she did not have any information available on the patient that received the vaccine. No lot number or expiration date provided. Batch/lot number was requested, not available at the time of call. Follow-up with caller was possible.  No additional information was available at time of call; caller declined to respond to questions and has accepted follow-up. This situation was reported as an off-label use as per local labelling due to administration technique. Case opened on 22-Apr-2022 at 15:30 to correct spelling of callers name. Additional Description of Adverse events: Disregard first transfer sheet. Correction was made to the name.  Action taken was not applicable.   Outcome was Unknown.     This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: MNQ
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: received a dose of expired MENACTRA today with no reported adverse event; Initial information received on 22-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health care professional.  This case involves an unknown age and unknown gender patient who  received a dose of expired menactra today with no reported adverse event while receiving  Meningococcal A-C-Y-W135 (D Conj) Vaccine [Menactra].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 22-Apr-2022, the patient received a  dose of suspect Meningococcal A-C-Y-W135 (D Conj) Vaccine  (lot number: U6921AB ,Expiration date : 17-Apr-2022)(strength, formulation, dosage, route, administration site :unknown for the suspect)  for immunization.  On an unknown date the patient developed non-serious sevent received a dose of expired menactra today with no reported adverse event (expired product administered) (unknown latency) following the administration of Meningococcal A-C-Y-W135 (D Conj) Vaccine.  Action taken : not applicable.  It was not reported if the patient received a corrective treatment for the event (received a dose of expired MENACTRA today with no reported adverse event).  At time of reporting, the outcome was Unknown for the event received a dose of expired menactra today with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 67.0
Sex: F
Vaccine: UNK
Symptoms: Injection site pain, Lymphadenopathy
Clinical narrative: Swelling in the lymph nodes under the arm pit; The injection site in the arm is sore; This spontaneous case was received on 24-Nov-2021 from other non-healthcare professional (consumer) via Agency (reference number: SEQW21-05638) and concerned a 67-year-old, female patient.  The patient's past medical history included lung cancer, a couple of years ago. The patient's historical vaccines included unspecified both Covid-19 vaccines used for an unreported indication. The patient was not taking any concomitant medications.   On an unspecified date in Oct-2021, reported as six weeks ago, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number was not reported.  On an unspecified date in Oct-2021, reported as six weeks ago, an unknown amount of time after receiving Fluad Quadrivalent, the patient experienced swelling in the lymph nodes under the armpit and the injection site in the arm was sore. The patient did not use any corrective treatment.  At the time of initial reporting on 24-Nov-2021, the patient had not recovered from swelling in the lymph nodes under the arm pit as the patient stated that she was still experiencing and that the swelling was reducing day by day but it was still bothering a lot.  The outcome of the vaccination site pain was unknown.  The reporter did not provide a causality assessment.   The case was assessed as non-serious.  Case updated on 26-Apr-2022: Correction made to information received on 24-Nov-2021: Regulatory authority was deleted from Intermediary field and Report Sent to Regulatory Authority by Reporter was changed from 'Yes' to 'Unk'. No changes in the narrative.  Company comment: A 67-year-old female patient experienced lymphadenopathy and vaccination site pain after receiving Fluad Quadrivalent. Based on information provided, causality for the reported events is assessed as possibly related.; Sender's Comments: A 67-year-old female patient experienced lymphadenopathy and vaccination site pain after receiving Fluad Quadrivalent. Based on information provided, causality for the reported events is assessed as possibly related.
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site rash, Injection site swelling
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Itch Generalized-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Fever-Severe, Systemic: rash at injection site-Medium
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Itch Generalized-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Fever-Severe, Systemic: rash at injection site-Medium
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Error: Expired Product Administered-
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Discomfort, Injection site pain, Pain
Clinical narrative: Site: Pain at Injection Site-Severe, Systemic: Chest Tightness / Heaviness / Pain-Severe, Systemic: pt states magnet sticks to injection site-Severe
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bronchoalveolar lavage, COVID-19, Chest X-ray abnormal, Cough, Dyspnoea
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 02/15/2021.  62 y/o female with PMHx of COPD, Asthma, HTN, Pulmonary HTN, Anemia, Type 2 Diabetes, Diabetic Neuropathy, OSA, Depression, Morbid obesity, home O2 presents to ED on 4/20 with c/o worsening SOB, cough and increased sputum production x1 week.  Initial Covid test negative. While at home, pt had to increase O2 from 2L to 3L-sats 92%.  Pt continued to require increased O2 and was eventually intubated on 4/22, also started on CRRT. 4/27, bronch washings positive for Covid.  CXR with diffuse interstitial and alveolar opactities.  Pt received IV ABX/steroids.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Endotracheal intubation, Haemofiltration, Lung opacity, SARS-CoV-2 test positive, Sputum increased
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 02/15/2021.  62 y/o female with PMHx of COPD, Asthma, HTN, Pulmonary HTN, Anemia, Type 2 Diabetes, Diabetic Neuropathy, OSA, Depression, Morbid obesity, home O2 presents to ED on 4/20 with c/o worsening SOB, cough and increased sputum production x1 week.  Initial Covid test negative. While at home, pt had to increase O2 from 2L to 3L-sats 92%.  Pt continued to require increased O2 and was eventually intubated on 4/22, also started on CRRT. 4/27, bronch washings positive for Covid.  CXR with diffuse interstitial and alveolar opactities.  Pt received IV ABX/steroids.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccine breakthrough infection
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 02/15/2021.  62 y/o female with PMHx of COPD, Asthma, HTN, Pulmonary HTN, Anemia, Type 2 Diabetes, Diabetic Neuropathy, OSA, Depression, Morbid obesity, home O2 presents to ED on 4/20 with c/o worsening SOB, cough and increased sputum production x1 week.  Initial Covid test negative. While at home, pt had to increase O2 from 2L to 3L-sats 92%.  Pt continued to require increased O2 and was eventually intubated on 4/22, also started on CRRT. 4/27, bronch washings positive for Covid.  CXR with diffuse interstitial and alveolar opactities.  Pt received IV ABX/steroids.
Age: 56.0
Sex: F
Vaccine: VARZOS
Symptoms: Hyperhidrosis, Influenza like illness, Injection site pain, Injection site swelling, Pain in extremity
Clinical narrative: Swelling and soreness at injection site, fever and sweating, sore arm, itchiness and hives, flu like symptoms.
Age: 56.0
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Pyrexia, Urticaria
Clinical narrative: Swelling and soreness at injection site, fever and sweating, sore arm, itchiness and hives, flu like symptoms.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Injection site pain, Joint range of motion decreased, Loss of personal independence in daily activities, Pain
Clinical narrative: A few days after the administration of the booster, I developed pain at the inection site in my upper right arm. Since that time the pain as increased. It radiates up to my shoulder and down to my wrist. It has affected my range of motion. I now have difficulty dressing. I often wake up at night with the pain. I am awaiting insurance since I started a new job. I have not been seen yet by a doctor. I know they will order xrays. I cannot afford that out of pocket expense at this time. I have to wait another month. I have been taking Naporxan 660 mg daily and applying Valteran gel on the affected areas of my arm. I plan on seeing a doctor as soon as I get my insurance.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Arthropathy, Magnetic resonance imaging joint
Clinical narrative: Extreme pain and weakness in both shoulders and left knee, followed by arthritic feeling in both hands.  The joints affected had previously been operated on. The knee in 1983, the right shoulder in 2013 and the left shoulder in 2015.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy skin, Rash erythematous, Rash pruritic, Skin irritation
Clinical narrative: She developed a rash that was red, itching, and skin irritated. She is taking hydroxyzine HCl 25 mg Oral - Dose: 1 tablet Frequency: q6h prn and using triamcinolone acetonide 0.1 % Topical - cream Frequency: bid
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Deafness neurosensory, Deafness unilateral, Magnetic resonance imaging head, Sudden hearing loss
Clinical narrative: Sudden Sensorneural Hearing Loss left ear
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Dizziness, Fatigue, Feeling abnormal, Mobility decreased
Clinical narrative: 1/19/2022 I felt a little crummy. On 1/22/2022 and 1/23/2022 I could not get out of bed, I was so fatigued. I also had tinnitus and dizziness. I was not sick. It just lasted over the week-end. I have lingering fatigue and tinnitus.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Tinnitus
Clinical narrative: 1/19/2022 I felt a little crummy. On 1/22/2022 and 1/23/2022 I could not get out of bed, I was so fatigued. I also had tinnitus and dizziness. I was not sick. It just lasted over the week-end. I have lingering fatigue and tinnitus.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: 2nd booster, dose #4 , was given too soon ; w/grace period 2nd booster was given 5 days too soon; pt felt well after administering vaccine and no concerns
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain
Clinical narrative: Client presented at a HCF vaccination site on 01.11.22. Client reported he received first dose of Pfizer COVID vaccine on 04/27/21 without any issues. Client reported received second dose of Pfizer COVID vaccine on 05/18/21, he had a headache and body ache for two hours after receiving the Pfizer COVID vaccine which lasted five to six hours. Client told he didn?t take any medications for his headache and body ache but just rested. Client reported he didn?t follow-up with his PCP. Client stated he doesn?t have any known allergy. Client denied any shortness of breath or any anaphylactic symptoms with both doses. Client reported he has history of migraine controlled with OTC CBD and ADHD controlled with Prozac. Today, he reported he has an 8/10 headache on a pain scale of 10 and consumed CBD four hours ago. Client is requesting for a booster dose of Pfizer COVID vaccine for a different day since client told he must return to work and is unable to wait for the approval but will call him once approval is received and reschedule him for a different day. PHN submitted a medical consult via text message to clinical project coordinator requesting to proceed with the booster dose of Pfizer COVID vaccine for a different day. Per the doctor, approval to proceed with the booster dose of Pfizer COVID vaccine was obtained via text message from clinical project coordinator. The booster dose of Pfizer COVID vaccine was not administered to client today since client left the vaccination site before his approval was received. PHN called client?s cell phone and left him a message that he got approved to come get his booster dose of Pfizer COVID vaccine when the vaccination site is open or call back if he has any questions.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia oral, Pharyngeal swelling, Throat tightness
Clinical narrative: I experienced prickling in my mouth, swelling in my throat to the point I felt like my throat was closing up. These symptoms lasted for 2 and a half hours, and I took antihistamines before going to the ER where I was given antihistamine and nausea medication.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Computerised tomogram thorax abnormal, Directional Doppler flow tests, Dyspnoea
Clinical narrative: The patient is an  85 y.o. female with past medical history of idiopathic pulmonary fibrosis/ hypothyroidism, hyperlipidemia, trigeminal neurology, history of recurrent syncope status post pacemaker placement, asthma. Presented to the emergency department at hospital with chief complaint of shortness of breath and was found to have acute COVID-19 infection and a large pericardial effusion.   Patient was discharged from Hospital 4/2/22 at that time she was admitted for acute on chronic hypoxic respiratory failure, and findings or pericardial effusion on CT scan, echocardiogram showed only trivial pericardial effusion.   She presented back to hospital with an acute onset of shortness of breath and dyspnea on exertion. Workup revealed a CT scan of the chest showing large pericardial effusion and COVID-19 positive.  She was transferred to hospital for further evaluation. A repeat echocardiogram revealed a small pericardial effusion is noted, predominantly adjacent to the mid to apical right ventricle. No tamponade physiology. This measures 1.2 cm in maximal dimension.  She remained on her home O2 settings of 2L. Given she is asymptomatic and with relatively small appearing pericardial effusion, she was discharged home in stable condition with plan to follow up with PCP and Cardiology. She will a follow up Echo to assess progression of pericardial effusion.   The patient has h/o recurrent UTI and due to her underlying pulmonary disease, our Pulmonary team recommended avoiding nitrofurantoin in the future due to her diagnosis of interstitial lung disease.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea exertional, Echocardiogram abnormal, Ejection fraction, Interstitial lung disease, Pericardial effusion
Clinical narrative: The patient is an  85 y.o. female with past medical history of idiopathic pulmonary fibrosis/ hypothyroidism, hyperlipidemia, trigeminal neurology, history of recurrent syncope status post pacemaker placement, asthma. Presented to the emergency department at hospital with chief complaint of shortness of breath and was found to have acute COVID-19 infection and a large pericardial effusion.   Patient was discharged from Hospital 4/2/22 at that time she was admitted for acute on chronic hypoxic respiratory failure, and findings or pericardial effusion on CT scan, echocardiogram showed only trivial pericardial effusion.   She presented back to hospital with an acute onset of shortness of breath and dyspnea on exertion. Workup revealed a CT scan of the chest showing large pericardial effusion and COVID-19 positive.  She was transferred to hospital for further evaluation. A repeat echocardiogram revealed a small pericardial effusion is noted, predominantly adjacent to the mid to apical right ventricle. No tamponade physiology. This measures 1.2 cm in maximal dimension.  She remained on her home O2 settings of 2L. Given she is asymptomatic and with relatively small appearing pericardial effusion, she was discharged home in stable condition with plan to follow up with PCP and Cardiology. She will a follow up Echo to assess progression of pericardial effusion.   The patient has h/o recurrent UTI and due to her underlying pulmonary disease, our Pulmonary team recommended avoiding nitrofurantoin in the future due to her diagnosis of interstitial lung disease.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory failure, SARS-CoV-2 test positive
Clinical narrative: The patient is an  85 y.o. female with past medical history of idiopathic pulmonary fibrosis/ hypothyroidism, hyperlipidemia, trigeminal neurology, history of recurrent syncope status post pacemaker placement, asthma. Presented to the emergency department at hospital with chief complaint of shortness of breath and was found to have acute COVID-19 infection and a large pericardial effusion.   Patient was discharged from Hospital 4/2/22 at that time she was admitted for acute on chronic hypoxic respiratory failure, and findings or pericardial effusion on CT scan, echocardiogram showed only trivial pericardial effusion.   She presented back to hospital with an acute onset of shortness of breath and dyspnea on exertion. Workup revealed a CT scan of the chest showing large pericardial effusion and COVID-19 positive.  She was transferred to hospital for further evaluation. A repeat echocardiogram revealed a small pericardial effusion is noted, predominantly adjacent to the mid to apical right ventricle. No tamponade physiology. This measures 1.2 cm in maximal dimension.  She remained on her home O2 settings of 2L. Given she is asymptomatic and with relatively small appearing pericardial effusion, she was discharged home in stable condition with plan to follow up with PCP and Cardiology. She will a follow up Echo to assess progression of pericardial effusion.   The patient has h/o recurrent UTI and due to her underlying pulmonary disease, our Pulmonary team recommended avoiding nitrofurantoin in the future due to her diagnosis of interstitial lung disease.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Cardioversion, Feeling abnormal, Ventricular tachycardia
Clinical narrative: Alert received in system on 1/15/21 at 1920 showing treated VT event.  Patient had what appears to be slow VT 136bpm for total duration of 1 min 25 sec.  Device attempted ATP 7 times unsuccessfully which then resulted in 1 shock at 22J which was successful.  Called and spoke with patient who says that he has received the COVID vaccine that morning.  He began to feel a bit run down in the afternoon and was aware that he received a shock.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Facial discomfort, Nausea, Vibratory sense increased
Clinical narrative: I experienced the right side of my face vibrating and nausea.
Age: 16.0
Sex: F
Vaccine: HEPA, MNQ
Symptoms: Incorrect dose administered
Clinical narrative: Patient was given the adult Hep A instead of pediatric dose
Age: 0.33
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV1
Symptoms: Rash erythematous
Clinical narrative: Developed four red spots on forehead and on one cheek- not raised, noted after giving vaccines, No distress, exam normal except noted above baby was given Benadryl, Rash resolved within a few minutes. Observed here for 30 minutes awake no distress or rash at discharge
Age: 55.0
Sex: M
Vaccine: VARZOS
Symptoms: Chills, Headache, Nausea, Pain, Pyrexia
Clinical narrative: Chills, fever, body aches, headache,  nausea
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus started 12/15/2021 and hasn't stopped.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Feeding disorder, Pyrexia, Stomatitis
Clinical narrative: FEVER, SORES IN MOUTH, UNABLE TO EAT FOR A WEEK
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Eczema, Fatigue, Myalgia, Nausea
Clinical narrative: Severe muscle aches as I had when having Mono, sore throat, extreme fatigue and nausea.  Eczema flare up on neck, ears and lower extremities with Prednisone 10mg tabs taken
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: Severe muscle aches as I had when having Mono, sore throat, extreme fatigue and nausea.  Eczema flare up on neck, ears and lower extremities with Prednisone 10mg tabs taken
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19 pneumonia, Positive airway pressure therapy, Respiratory failure
Clinical narrative: Acute hypoxemic and hypercapnic respiratory failure; COVID-19 pneumonia. Treated with BiPAP and O2 through patient's own airway.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Asthenia, COVID-19, Condition aggravated
Clinical narrative: 04/03/2022 My larynx was getting full of mucus. I felt a cough coming on and felt weak. I have a history of bowel issues and it became worse at this time. I was very tired, I started trying to sleep and rest. I had no fever. I had congestion. I developed a cough that began as tickling, dry and became worse. I lost my sense of taste and smell. 04/04/2022 I took a COVID-19 home test and it was positive. I have been exercising and biking and I feel pretty much recovered except for congestion and mild coughing.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Fatigue, Gastrointestinal disorder, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: 04/03/2022 My larynx was getting full of mucus. I felt a cough coming on and felt weak. I have a history of bowel issues and it became worse at this time. I was very tired, I started trying to sleep and rest. I had no fever. I had congestion. I developed a cough that began as tickling, dry and became worse. I lost my sense of taste and smell. 04/04/2022 I took a COVID-19 home test and it was positive. I have been exercising and biking and I feel pretty much recovered except for congestion and mild coughing.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Secretion discharge
Clinical narrative: 04/03/2022 My larynx was getting full of mucus. I felt a cough coming on and felt weak. I have a history of bowel issues and it became worse at this time. I was very tired, I started trying to sleep and rest. I had no fever. I had congestion. I developed a cough that began as tickling, dry and became worse. I lost my sense of taste and smell. 04/04/2022 I took a COVID-19 home test and it was positive. I have been exercising and biking and I feel pretty much recovered except for congestion and mild coughing.
Age: 82.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature increased, COVID-19, Chest X-ray normal, Cough, Hypotension
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 01/05/2021.  83 y/o male with PMHx of Parkinson's, HTN, Hypothyroidism, HLD, BPH, Bipolar, Depression, anxiety presents to ED with c/o cough, nasal congestion and sore throat.  Pt tested positive for Covid at his ALF where he was also found to be hypotensive, one day prior to arrival.  In ED, pt with low grade temp, room air sat 96% and CXR with no acute changes.  No immediate treatment for Covid ordered.
Age: 82.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nasal congestion, Oropharyngeal pain, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 01/05/2021.  83 y/o male with PMHx of Parkinson's, HTN, Hypothyroidism, HLD, BPH, Bipolar, Depression, anxiety presents to ED with c/o cough, nasal congestion and sore throat.  Pt tested positive for Covid at his ALF where he was also found to be hypotensive, one day prior to arrival.  In ED, pt with low grade temp, room air sat 96% and CXR with no acute changes.  No immediate treatment for Covid ordered.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Bronchoalveolar lavage abnormal, COVID-19, Pyrexia
Clinical narrative: Hospitalized all negative nasopharynx swabs for COVID, bronc lavage is SARS COV2 RNA positive on 4/22. Polyarticular joint pain, weakness and fever, has UTI.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 RNA, SARS-CoV-2 test positive, Urinary tract infection
Clinical narrative: Hospitalized all negative nasopharynx swabs for COVID, bronc lavage is SARS COV2 RNA positive on 4/22. Polyarticular joint pain, weakness and fever, has UTI.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Cough, Exposure to SARS-CoV-2, Headache
Clinical narrative: My 8-year tested positive for COVID-19 on December 31st. I was tested on January 06 for COVID-19 and it was positive also. I experienced tons of congestion, low energy and a headache. I did not have a lot of coughing. When we tested positive, we just monitored ourselves. We did not go see a doctor, I just managed it with Dayquil. I did make a complete recovery after about 8 to 10 days.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: My 8-year tested positive for COVID-19 on December 31st. I was tested on January 06 for COVID-19 and it was positive also. I experienced tons of congestion, low energy and a headache. I did not have a lot of coughing. When we tested positive, we just monitored ourselves. We did not go see a doctor, I just managed it with Dayquil. I did make a complete recovery after about 8 to 10 days.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Pain in extremity, Sleep disorder
Clinical narrative: Starting within a few days after receiving the vaccine, I awoke from a dead sleep due to severe arm pain in the right arm. I thought it was paralyzed or I had a stroke. I lifted my right arm with my other arm. I went back to sleep and when I woke up I still had some weakness in the right arm. When I went to my PCP in September and mentioned this event. She told me to see physical therapy if it got worse. Eventually it did get worse, so I am going to do physical therapy in a few weeks. Also, I was referred to a Sports Medicine doctor and, after describing what happened to me, he is skeptical but will go ahead and perform an EMG to test for nerve damage.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Nasal congestion, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: I woke up 4/25/22 with a sore throat and as the day progressed I developed a cough, and when I got home that evening and I was coughing more and I never cough and had stuffed up sinuses and the next morning I did a virtual visit and was prescribed Paxlovid the next day.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Flushing, Grunting, Hyperhidrosis, Skin warm
Clinical narrative: Gave patient vaccine at 4:00 pm, at 4:02 heard patient making what sounded like grunting noises then heard his phone fall.  When we looked out the patient was standing and just staring blankly.  Went out to patient and tried asking him symptoms.  Patient nodded when asked if he was short of breath.  I grabbed patient and got him back into the seat.  He was extremely hot and drenched in sweat.  Patient was still conscious but not responding to any further questions.  At this point decided to administer epipen due to patient previously acknowledging shortness of breath and flushing even though did not notice hives or swelling.  Technician called ems in the meantime, they arrived in about 10 minutes.  Patient was still conscious but still not responding.  EMS put him on stretcher and took to ambulance.  I talked to patient later that night and said he was feeling better but had no recollection of anything until being in ambulance.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Staring, Unresponsive to stimuli
Clinical narrative: Gave patient vaccine at 4:00 pm, at 4:02 heard patient making what sounded like grunting noises then heard his phone fall.  When we looked out the patient was standing and just staring blankly.  Went out to patient and tried asking him symptoms.  Patient nodded when asked if he was short of breath.  I grabbed patient and got him back into the seat.  He was extremely hot and drenched in sweat.  Patient was still conscious but not responding to any further questions.  At this point decided to administer epipen due to patient previously acknowledging shortness of breath and flushing even though did not notice hives or swelling.  Technician called ems in the meantime, they arrived in about 10 minutes.  Patient was still conscious but still not responding.  EMS put him on stretcher and took to ambulance.  I talked to patient later that night and said he was feeling better but had no recollection of anything until being in ambulance.
Age: 90.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Decreased appetite, Eye irritation, Pain, SARS-CoV-2 test positive
Clinical narrative: BODY ACHES AND PAIN ALL OVER BODY. EYE  IRRITATION,, NO APPETITE
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Erythema, Inflammation, Pruritus, Swelling
Clinical narrative: swelling, burning, itchy, inflamed red raised large area covering arm
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Fall, Fatigue, Feeling abnormal
Clinical narrative: That evening I felt flu-like symptoms.  The next morning, at 5:50 AM I passed out for 5 minutes.  When I came to it was 5:55 AM.  I must  have broken the fall by extending my arms so that my head did not hit the floor.  A few hours later, I had significant pain in my neck. shoulder and back.   The flu like symptoms lasted for 2-3 days.  After that, I was exhausted for another week.  I really did not feel myself for a few weeks.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza like illness, Loss of consciousness, Neck pain
Clinical narrative: That evening I felt flu-like symptoms.  The next morning, at 5:50 AM I passed out for 5 minutes.  When I came to it was 5:55 AM.  I must  have broken the fall by extending my arms so that my head did not hit the floor.  A few hours later, I had significant pain in my neck. shoulder and back.   The flu like symptoms lasted for 2-3 days.  After that, I was exhausted for another week.  I really did not feel myself for a few weeks.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Rhinorrhoea, SARS-CoV-2 test
Clinical narrative: runny nose, mild cough